Childrens Mercy Hospital
- Type
- Teaching hospital
- Where
- Kansas City, MO
- Medicare CCN
- 263302
- Received
- $3,027,122 in 377 records, 2022 ($184,950 general, $2,842,172 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE CHILDRENS MERCY HOSPITAL CORPORATION Fuzzy (name and state)
- Federal award recipient: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
- Nonprofit: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 28 | $184,950 |
| 2022 | Research payment | 349 | $2,842,172 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 349 | $2,842,172 |
| Charitable Contribution | 4 | $100,625 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $79,780 |
| Long term medical supply or device loan | 10 | $2,493 |
| Space rental or facility fees (teaching hospital only) | 6 | $1,900 |
| Debt forgiveness | 1 | $151 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $13,245 | Research payment | In-kind items and services | TCMH2022MRIPR9329419919961093Artz | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $13,245 | Research payment | In-kind items and services | TCMH2022MRIPR9329419919961093Artz | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $4,125 | Research payment | In-kind items and services | CMH2021MRIPR992Artz | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $166 | Research payment | In-kind items and services | RAGWITEK Biological, RESPIRATORY | A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed Ambros | 2022 |
| 2022-12-31 | Masimo Corporation | $80 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $80 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $80 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $80 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $56 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Sub | 2022 |
| 2022-12-30 | bioMerieux Inc | $18,000 | Research payment | Cash or cash equivalent | SpotFire R/ST Prospective Study | 2022 | |
| 2022-12-30 | bioMerieux Inc | $11,030 | Research payment | Cash or cash equivalent | SpotFire R/ST Prospective Study | 2022 | |
| 2022-12-27 | PENTAX of America, Inc. | $1,364 | Long term medical supply or device loan | Cash or cash equivalent | PENTAX Device, Gastroenterology | 2022 | |
| 2022-12-27 | Masimo Corporation | $79 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-27 | Masimo Corporation | $79 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-27 | Masimo Corporation | $79 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-27 | Masimo Corporation | $79 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-22 | Abbott Laboratories | $100,000 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-12-22 | Gilead Sciences, Inc. | $8,927 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-12-22 | VERTEX PHARMACEUTICALS INCORPORATED | $3,114 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With | 2022 | |
| 2022-12-22 | ABBVIE INC. | $2,183 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulat | 2022 |
| 2022-12-22 | ALBIREO PHARMA, INC. | $1,470 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-12-22 | ALBIREO PHARMA, INC. | $670 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2022 |
| 2022-12-22 | Draeger Medical Systems, Inc | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BIRTHING ROOM WARMER Device, Neonatal Care & Warming Therapy | 2022 | |
| 2022-12-22 | ALBIREO PHARMA, INC. | $450 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-12-22 | ALBIREO PHARMA, INC. | $397 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2022 |
| 2022-12-21 | bioMerieux Inc | $5,537 | Research payment | Cash or cash equivalent | SpotFire R/ST Prospective Study | 2022 | |
| 2022-12-21 | Ultragenyx Pharmaceutical Inc. | $3,632 | Research payment | Cash or cash equivalent | UX143-CL301 | 2022 | |
| 2022-12-19 | Edwards Lifesciences Corporation | $3,580 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-12-19 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b | 2022 |
| 2022-12-19 | Edwards Lifesciences Corporation | $300 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-12-19 | Edwards Lifesciences Corporation | $204 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-12-16 | Rhythm Pharmaceuticals, Inc. | $23,630 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-12-15 | PFIZER INC. | $7,250 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS | 2022 |
| 2022-12-15 | Eli Lilly and Company | $56 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL PHASE 1/2 STUDY EVALUATING RAMUCIRUMAB IN PEDIATRIC PATIENTS AND YOUNG ADULTS WITH RELAPSED, RE | 2022 | |
| 2022-12-12 | Edwards Lifesciences Corporation | $3,570 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-12-12 | Edwards Lifesciences Corporation | $2,040 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-12-12 | Edwards Lifesciences Corporation | $2,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-12-12 | Edwards Lifesciences Corporation | $596 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-12-12 | Gilead Sciences, Inc. | $500 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-12-12 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-12-12 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-12-12 | Edwards Lifesciences Corporation | $177 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-12-12 | Gilead Sciences, Inc. | $30 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2022 |
| 2022-12-07 | PFIZER INC. | $44,171 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-12-07 | Edwards Lifesciences Corporation | $2,040 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-12-07 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-12-07 | GLOBAL BLOOD THERAPEUTICS, INC. | $90 | Research payment | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | GBT_GBT440-038_3702_01 | 2022 |
| 2022-12-05 | Gilead Sciences, Inc. | $500 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-12-05 | Gilead Sciences, Inc. | $60 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2022 |
| 2022-12-02 | Aimmune Therapeutics, Inc. | $66 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2022 |
| 2022-12-02 | Aimmune Therapeutics, Inc. | $33 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2022 |
| 2022-11-28 | Gilead Sciences, Inc. | $4,360 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $15,514 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $5,600 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $5,460 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $5,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $4,080 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $3,994 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $3,640 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $3,500 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $2,174 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $1,365 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $900 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $817 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $800 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $715 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $688 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $400 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $177 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $88 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2022 |
| 2022-11-23 | Novo Nordisk AS | $630 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2022 |
| 2022-11-22 | bioMerieux Inc | $107 | Research payment | Cash or cash equivalent | SpotFire R/ST Prospective Study | 2022 | |
| 2022-11-16 | PFIZER INC. | $518 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-11-15 | PFIZER INC. | $36,421 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-11-04 | Catalent Pharma Solutions, LLC | $25 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-11-03 | ALBIREO PHARMA, INC. | $210 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2022 |
| 2022-11-02 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b | 2022 |
| 2022-10-31 | bioMerieux Inc | $13,614 | Research payment | Cash or cash equivalent | SpotFire R/ST Prospective Study | 2022 | |
| 2022-10-26 | Aimmune Therapeutics, Inc. | $1,990 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2022 |
| 2022-10-21 | National Marrow Donor Program | $2,245 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-10-20 | ALBIREO PHARMA, INC. | $8,499 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2022 |
| 2022-10-20 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2022 | |
| 2022-10-20 | ALBIREO PHARMA, INC. | $400 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-10-19 | Gilead Sciences, Inc. | $1,300 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-10-19 | Gilead Sciences, Inc. | $587 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2022 |
| 2022-10-13 | ALBIREO PHARMA, INC. | $1,500 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-10-13 | ALBIREO PHARMA, INC. | $990 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-10-13 | bioMerieux Inc | $198 | Research payment | Cash or cash equivalent | SpotFire R/ST Prospective Study | 2022 | |
| 2022-10-12 | Gilead Sciences, Inc. | $220 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-10-10 | Edwards Lifesciences Corporation | $7,650 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-10-10 | Edwards Lifesciences Corporation | $3,600 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-10-10 | Edwards Lifesciences Corporation | $2,040 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-10-10 | OpGen, Inc. | $2,000 | Research payment | Cash or cash equivalent | Acuitas | 2022 | |
| 2022-10-10 | Edwards Lifesciences Corporation | $1,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-10-10 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-10-10 | Edwards Lifesciences Corporation | $568 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-10-10 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-10-10 | Gilead Sciences, Inc. | $175 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2022 |
| 2022-10-07 | GLOBAL BLOOD THERAPEUTICS, INC. | $3,000 | Research payment | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2022 |
| 2022-10-06 | ALBIREO PHARMA, INC. | $3,571 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-10-06 | ALBIREO PHARMA, INC. | $2,906 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2022 |
| 2022-10-01 | PFIZER INC. | $34,821 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-10-01 | bioMerieux Inc | $13,500 | Research payment | Cash or cash equivalent | GI Sample Type Addition Prospective Study | 2022 | |
| 2022-09-28 | PFIZER INC. | $165 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-09-22 | ALBIREO PHARMA, INC. | $16,800 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2022 |
| 2022-09-22 | ALBIREO PHARMA, INC. | $1,454 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-09-22 | Luminex Corporation | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-09-22 | ALBIREO PHARMA, INC. | $1,013 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2022 |
| 2022-09-21 | Gilead Sciences, Inc. | $5,129 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-09-21 | Gilead Sciences, Inc. | $1,220 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2022 |
| 2022-09-19 | Gilead Sciences, Inc. | $555 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2022 |
| 2022-09-16 | GE HEALTHCARE | $8,500 | Research payment | In-kind items and services | Bridging the dosing gap with UGAP in pedriatic obesity | 2022 | |
| 2022-09-15 | Edwards Lifesciences Corporation | $5,100 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-09-15 | Edwards Lifesciences Corporation | $3,060 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-09-15 | Edwards Lifesciences Corporation | $2,400 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-09-15 | ALBIREO PHARMA, INC. | $1,785 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-09-15 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-09-15 | Edwards Lifesciences Corporation | $568 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-09-15 | Edwards Lifesciences Corporation | $400 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-09-15 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-09-06 | Abbott Laboratories | $3,000 | Research payment | Cash or cash equivalent | FREESTYLE LIBRE 2 Device, Diabetes Care | FreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG | 2022 |
| 2022-09-06 | Abbott Laboratories | $3,000 | Research payment | Cash or cash equivalent | FREESTYLE LIBRE 2 Device, Diabetes Care | FreeStyle Libre 2 Flash Glucose Monitoring System Control Phase Study for Pediatric Patients - BG | 2022 |
| 2022-09-06 | ZOLL Medical Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, DEFIBRILLATOR | 2022 | |
| 2022-08-31 | Janssen Research & Development, LLC | $3,600 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | CNTO1275CRD3010 | 2022 |
| 2022-08-31 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | CNTO1275CRD3010 | 2022 |
| 2022-08-30 | Organon Llc | $55,391 | Research payment | Cash or cash equivalent | A quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con | 2022 | |
| 2022-08-30 | Organon Llc | $27,695 | Research payment | Cash or cash equivalent | A quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con | 2022 | |
| 2022-08-24 | PFIZER INC. | $34,638 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-24 | Novo Nordisk AS | $1,464 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2022 |
| 2022-08-24 | PFIZER INC. | $345 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-08-24 | PFIZER INC. | $206 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-08-23 | GLOBAL BLOOD THERAPEUTICS, INC. | $180 | Research payment | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | GBT_GBT440-038_3702_01 | 2022 |
| 2022-08-19 | Novo Nordisk AS | $410 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2022 |
| 2022-08-18 | ALBIREO PHARMA, INC. | $1,785 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-08-17 | PFIZER INC. | $3,789 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-11 | Ultragenyx Pharmaceutical Inc. | $12,518 | Research payment | Cash or cash equivalent | UX143-CL301 | 2022 | |
| 2022-08-11 | Ultragenyx Pharmaceutical Inc. | $5,120 | Research payment | Cash or cash equivalent | UX143-CL301 | 2022 | |
| 2022-08-11 | Ultragenyx Pharmaceutical Inc. | $4,655 | Research payment | Cash or cash equivalent | UX143-CL301 | 2022 | |
| 2022-08-11 | Ultragenyx Pharmaceutical Inc. | $1,995 | Research payment | Cash or cash equivalent | UX143-CL301 | 2022 | |
| 2022-08-11 | Ultragenyx Pharmaceutical Inc. | $1,330 | Research payment | Cash or cash equivalent | UX143-CL301 | 2022 | |
| 2022-08-10 | PFIZER INC. | $22,636 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-10 | Edwards Lifesciences Corporation | $6,400 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-08-10 | Edwards Lifesciences Corporation | $4,080 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-08-10 | Edwards Lifesciences Corporation | $3,060 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-08-10 | Edwards Lifesciences Corporation | $400 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-08-10 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-08-10 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-08-10 | Edwards Lifesciences Corporation | $177 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-08-08 | ZOLL Medical Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, DEFIBRILLATOR | 2022 | |
| 2022-08-05 | National Marrow Donor Program | $2,305 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-08-04 | PFIZER INC. | $20,654 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-04 | ALBIREO PHARMA, INC. | $11,596 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-08-04 | ALBIREO PHARMA, INC. | $8,845 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2022 |
| 2022-08-04 | ALBIREO PHARMA, INC. | $5,877 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2022 |
| 2022-08-04 | ALBIREO PHARMA, INC. | $2,693 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2022 |
| 2022-08-03 | PFIZER INC. | $281 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-08-03 | PFIZER INC. | $206 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-08-03 | PFIZER INC. | $172 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-08-03 | PFIZER INC. | $29 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-08-02 | PFIZER INC. | $167,745 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-01 | ABBVIE INC. | $5,715 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulat | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $8,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $6,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $4,550 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $4,080 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $3,750 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $3,570 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $600 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $568 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2022 |
| 2022-07-28 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2022 |
| 2022-07-27 | Gilead Sciences, Inc. | $2,500 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-07-27 | ALBIREO PHARMA, INC. | $2,340 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patient | 2022 |
| 2022-07-27 | Novartis Pharmaceuticals Corporation | $1,114 | Research payment | Cash or cash equivalent | KYMRIAH Biological, ONCOLOGY | A SINGLE ARM PHASE II TRIAL IN FIRST LINE HIGH RISK HR PEDIATRIC AND YOUNG ADULT PATIENTS WITH BCELL ACUTE LYMPHOBLASTIC | 2022 |
| 2022-07-25 | Carl Zeiss Meditec, Inc. | $151 | Debt forgiveness | In-kind items and services | 2022 | ||
| 2022-07-22 | Aimmune Therapeutics, Inc. | $2,080 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2022 |
| 2022-07-22 | National Marrow Donor Program | $257 | Research payment | Cash or cash equivalent | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation | 2022 | |
| 2022-07-21 | GLOBAL BLOOD THERAPEUTICS, INC. | $3,678 | Research payment | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | GBT_GBT440-038_3702_01 | 2022 |
| 2022-07-20 | Gilead Sciences, Inc. | $1,460 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-07-18 | Abbott Laboratories | $8,026 | Research payment | Cash or cash equivalent | FREESTYLE LIBRE 2 Device, Diabetes Care | FreeStyle Libre 2 flash Glucose Monitoring System Intervention Phase Study for Pediatric Patients-FreeStyle Libre 2 | 2022 |
| 2022-07-18 | Dexcom, Inc. | $85 | Research payment | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | Artificial Intelligence-enables Meal Detection to promote insulin Dose Engagement in Adolescents with Type 1 Diabetes (A | 2022 |
| 2022-07-15 | ABBVIE INC. | $1,200 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b | 2022 |
| 2022-07-13 | HEMA Biologics, LLC | $16,000 | Research payment | Cash or cash equivalent | SevenFact Biological, Hematology | ATHN 16 | 2022 |
| 2022-07-02 | Novo Nordisk AS | $790 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4467 | 2022 |
| 2022-07-01 | bioMerieux Inc | $40,500 | Research payment | Cash or cash equivalent | GI Sample Type Addition Prospective Study | 2022 | |
| 2022-06-30 | JAZZ PHARMACEUTICALS INC. | $135,375 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-06-29 | PFIZER INC. | $281 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-06-29 | PFIZER INC. | $172 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-06-29 | PFIZER INC. | $41 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-06-29 | PFIZER INC. | $29 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-06-27 | Aimmune Therapeutics, Inc. | $2,080 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2022 |
| 2022-06-24 | Hyperfine Operations, Inc. | $44,277 | Research payment | Cash or cash equivalent | Swoop Device, Portable MRI | Clinical Validation of Point of Care Hyperfine MRI in Children: A Pilot Study | 2022 |
| 2022-06-24 | Novartis Pharmaceuticals Corporation | $105 | Research payment | Cash or cash equivalent | KYMRIAH Biological, ONCOLOGY | LONG TERM FOLLOW UP OF PATIENTS EXPOSED TO LENTIVIRAL BASED CD19 DIRECTED CAR T CELL THERAPY | 2022 |
| 2022-06-22 | Gilead Sciences, Inc. | $4,974 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-06-16 | ABBVIE INC. | $3,250 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b | 2022 |
| 2022-06-14 | Dexcom, Inc. | $2,871 | Research payment | Cash or cash equivalent | Dexcom G6 Transmitter Medical Supply, Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2022 |
| 2022-06-14 | PFIZER INC. | $89 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2022 |
| 2022-06-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $55,828 | Research payment | Cash or cash equivalent | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2022 |
The latest 200 records of 377.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Kansas City, MO | County Jackson County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 510,612 | 719,976 | 6,191,814 |
| Population, 2020 census P1 | 508,090 | 717,204 | 6,154,913 |
| Median age B01002 | 35.8 | 37.0 | 39.0 |
| Under 18 B01001 | 22.5% | 23.3% | 22.3% |
| 65 and over B01001 | 14.3% | 15.9% | 17.9% |
| Households B11001 | 221,979 | 306,798 | 2,508,227 |
| Foreign born B05002 | 8.6% | 6.6% | 4.5% |
| Median household income B19013 | $69,166 | $68,577 | $70,702 |
| Median family income B19113 | $92,934 | $90,585 | $91,360 |
| Per capita income B19301 | $41,393 | $39,559 | $39,695 |
| Poverty rate B17001 | 14.6% | 14.1% | 12.6% |
| Unemployment rate B23025 | 4.4% | 4.7% | 4.0% |
| Civilian labor force B23025 | 279,828 | 381,433 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.7 | 23.4 | 23.5 |
| Bachelor's degree or higher B15003 | 38.4% | 34.0% | 32.4% |
| Housing units B25001 | 245,346 | 336,288 | 2,825,287 |
| Owner-occupied B25003 | 55.4% | 59.1% | 68.1% |
| Renters B25003 | 44.6% | 40.9% | 31.9% |
| Median home value B25077 | $242,900 | $230,500 | $230,300 |
| Median gross rent B25064 | $1,238 | $1,197 | $1,033 |
| White, not Hispanic B03002 | 54.0% | 59.3% | 76.3% |
| Black B03002 | 25.2% | 22.0% | 10.9% |
| Hispanic or Latino B03002 | 12.5% | 11.4% | 5.2% |
| Asian B03002 | 2.8% | 1.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.
Comments